300972 Fujian Wanchen Biotechnology Group
- 51.88
- -3.00-5.47%
Fujian Wanchen Biotechnology Group News
Wanchen Group: An indicative announcement of Fujian Wanchen Biotechnology Group Co., Ltd. on shareholders\' signing of share transfer agreements and changes in equity
Wan Chen Group: Simplified Equity Report - Fujian Mimosa Agricultural Development Co., Ltd., Zhangzhou Jinwanchen Investment Co., Ltd.
Wanchen Group: Simplified Equity Report - Peng Dejian
Wanchen Group: Legal Opinion of Attorney Guohao (Beijing) Firm on the 5th Extraordinary General Meeting of Shareholders of Fujian Wanchen Biotechnology Group Co., Ltd. in 2024
Wanchen Group: Announcement of Resolutions of the Fifth Extraordinary General Meeting of Shareholders in 2024
Wanchen Group: Fujian Wanchen Biotechnology Group Co., Ltd. Investor Relations Activity Record
Wanchen Group: Announcement of Resolutions of the 18th Meeting of the Fourth Board of Directors
Wanchen Group: Notice on Convening the Fifth Extraordinary General Meeting of Shareholders of the Company in 2024
Wanchen Group: Review Opinions of the 6th Special Meeting of Independent Directors of the 4th Board of Directors
Wanchen Group: Huaxing Securities Co., Ltd.\'s inspection opinion on the financial support provided by Nanjing Wanhao Commercial Management Co., Ltd., a holding subsidiary of Fujian Wanchen Biotechnology Group Co., Ltd., to the holding subsidiary Nanjing Wantuo Commercial Management Co., Ltd.
Wanchen Group: Announcement of Resolutions of the 19th Meeting of the Fourth Board of Supervisors
Wanchen Group: Announcement on the provision of financial support to the holding subsidiary Nanjing Wanhao Commercial Management Co., Ltd. to the holding subsidiary Nanjing Wantuo Commercial Management Co., Ltd.
Wanchen Group: Announcement on the results of assigning part of the first vesting period of the second restricted stock incentive plan in 2023 and the listing of shares
Wanchen Group: Announcement on the establishment of a special settlement account for the management of raised funds and cash
Wanchen Group: Huaxing Securities Co., Ltd.\'s 2024 semi-annual continuous supervision and follow-up report on Fujian Wanchen Biotechnology Group Co., Ltd.
Fujian Wanchen Biotechnology Group: Announcement regarding the cancellation of the unallocated restricted shares under the Company's 2023 second phase restricted stock incentive plan.
Fujian Wanchen Biotechnology Group: Supervisory Board's verification opinion on the first attribution list of the first vesting period of the Company's second phase of restricted stocks incentive plan in 2023.
Fujian Wanchen Biotechnology Group: Guohao Law Firm (Beijing) Legal Opinion on the First Grant of Restricted Stock Incentive Plan for the Second Period of Fujian Wanchen Biotechnology Group Co., Ltd. in 2023, Achieving Some Attribution Achievements for the First Attribution Period and Invalidation of Some Restricted Stocks.
Fujian Wanchen Biotechnology Group: Announcement of the resolution of the 18th meeting of the 4th Board of Supervisors.
Fujian Wanchen Biotechnology Group: Announcement on the achievement of the first attribution period attribution conditions under the first grant part of the second phase of the company's 2023 restricted stock incentive plan.
Analysis
Price Target
No Data
No Data